Clinical Study of the Efficacy and Safety of XPO-1 Inhibitors in Combination With CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
Latest Information Update: 07 Mar 2024
At a glance
- Drugs CAR-T cell therapies (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Selinexor (Primary)
- Indications B-cell lymphoma; Burkitt's lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man; Therapeutic Use
Most Recent Events
- 15 Jun 2023 Results (n=6) of preliminary data assessing sequential use of Selinexor and CART19 was initiated with the aim of prolong relapse-free survival of CART19 cells therapy in R/R B-NHL patients presented at the 28th Congress of the European Haematology Association
- 07 Feb 2023 Planned number of patients changed from 10 to 20.
- 15 Apr 2022 New trial record